Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at zalutumumab with radiotherapy for head and neck cancer (GEN207)
Cancer type:
Head and neck cancers
Laryngeal cancer
Mouth (oral) cancer
Status:
Results
Phase:
Phase 1/2
This trial was looking at zalutumumab with radiotherapy for cancer of the mouth or cancer of the voice box (larynx) that is locally advanced.
Doctors often treat locally advanced cancer of the mouth or cancer of the larynx with chemotherapy and radiotherapy together. They most often use 
. But some people are not able to have platinum drugs.
Zalutumumab is a type of biological therapy called a monoclonal antibody. We knew from that zalutumumab may stop or slow down the growth of cancer cells.
The aim of this trial was to find the of zalutumumab to use with radiotherapy.
Summary of results
This trial was never finished so there are no results available.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Chief Investigator
Prof Chris Nutting
Supported by
Experimental Cancer Medicine Centre (ECMC)
Genmab
NIHR Clinical Research Network: Cancer
Questions about cancer? Contact our information nurses
Freephone 0808 800 4040
Last review date
CRUK internal database number:
Oracle 3749
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
Over 60,000 cancer patients enrolled on clinical trials in the UK last year.
Last reviewed:
About Cancer generously supported by
Dangoor Education since 2010.
Dangoor Education since 2010.